[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"systemic-inflammatory-response\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:systemic-inflammatory-response":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,50,81,114],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100644724","ulinastatin-on-systemic-immune-inflammation-in-patients-with-complicated-intra-abdominal-infection-100644724",false,"NCT07672496","Ulinastatin on Systemic Immune-Inflammation in Patients With Complicated Intra-Abdominal Infection","A Single-Center Randomized Controlled Pilot Study on the Effect of Ulinastatin on Systemic Immune and Inflammatory Response in Patients With Complicated Intra-Abdominal Infection","UTI-cIAI","Inclusion Criteria:\n\n1. Able to provide written informed consent voluntarily.\n2. Age ≥ 18 years old, any gender.\n3. Diagnosed with severe complicated intra-abdominal infection (cIAI) within 48 hours, consistent with the 2025 expert consensus for cIAI diagnosis. Diagnosis is confirmed by clinical symptoms (fever, abdominal pain, distension, etc.), abdominal imaging (CT\u002Fultrasound\u002FMRI), intraoperative findings, or positive pathogen culture of abdominal drainage fluid.\n4. Baseline Sequential Organ Failure Assessment (SOFA) score ≥ 2 points.\n\nExclusion Criteria:\n\n1. Severe immune deficiency conditions, including AIDS, prior solid organ or bone marrow transplantation, HIV infection with CD4 count \\\u003C 200 cells\u002Fmm³, long-term high-dose glucocorticoid therapy (prednisone \\> 20 mg\u002Fday), ongoing chemotherapy for malignant tumors, or absolute neutrophil count \\\u003C 1000 cells\u002Fmm³.\n2. Severe irreversible underlying diseases, including chronic renal failure requiring dialysis, Child-Pugh grade C liver disease, liver disease with severe portal hypertension, or acute liver failure.\n3. Patients with active malignant tumors, pregnancy, or severe psychiatric disorders.\n4. American Society of Anesthesiologists (ASA) physical status grade IV or above.\n5. Severe coagulation disorder defined as ISTH-DIC score ≥ 5 points.\n6. Critically ill patients with expected death within 48 hours after admission.\n7. Known allergy to ulinastatin or any ingredients of the study preparation.\n8. Any condition that, in the judgment of the principal investigator, makes the patient inappropriate for trial participation.","ALL","18 Years",{"count":20,"type":21},165,"ESTIMATED","INTERVENTIONAL",[24],"NA","Complicated intra-abdominal infection (cIAI) triggers dysregulated systemic inflammation and immune paralysis leading to high organ failure and death risk. Ulinastatin is a protease inhibitor with anti-inflammatory properties, but its dose-related effects on immune-inflammation of cIAI patients remain unclear. This single-center single-blinded three-arm randomized controlled pilot study enrolls adult cIAI patients (≥18 years, SOFA≥2) at Fujian Medical University Union Hospital. Eligible patients are randomized into low-dose ulinastatin, high-dose ulinastatin and normal saline placebo groups (1:1:1, 5 days intravenous treatment plus standard care), total planned enrollment 165 participants after 10% dropout adjustment. Primary endpoint is Day5 change of Systemic Immune-Inflammation Index (SII); secondary outcomes include serial inflammatory biomarkers, SOFA variation, organ dysfunction, hospitalization duration, 28-day mortality and safety profiles. This pilot aims to clarify ulinastatin's immune-modulating effect and inform future large RCT design.",[27,28,29,30],"Complicated Intra-abdominal Infection (cIAI)","Systemic Inflammatory Response","Sepsis","Immune Dysfunction",[32,33,34,35,36],"immune dysfunction","Complicated intra-abdominal infection","Ulinastatin","SII","inflammation","NOT_YET_RECRUITING","2026-06-26",{"date":40,"type":41},"2026-06-29","ACTUAL",{"date":43,"type":21},"2026-10-30",{"date":45,"type":21},"2028-06-30",{"name":47,"class":48},"Fujian Medical University Union Hospital","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":49},"100569513","improving-health-outcomes-with-kefir-100569513","NCT06695221","Improving Health Outcomes With Kefir","Inclusion Criteria:\n\n1. females and males (24-70 years old) living in Edmonton (or Edmonton area\u002Fdriving distance);\n2. overweight or obesity (BMI \\>25 Caucasian, \\>23 Asian);\n3. at higher risk of T2D (fasting blood glucose ≥ 5.6 - 6.9 mmol\u002FL or\u002Fand HbA1C ≥ 5.5 - 6.4%); or\n4. with diagnosis of T2D (fasting blood glucose ≥ 7.0 mmol\u002FL or\u002Fand HbA1C ≥ 6.5%).\n\nExclusion Criteria:\n\n1. a usual high intake (maximum intake 3 servings\u002Fweek) of fermented foods excluding cheese (i.e., kefir, kombucha, kimchi, etc.) for the past 3 months;\n2. gastrointestinal (GI) disorders of any kind;\n3. being pregnant or breastfeeding;\n4. monogenic dyslipidemias and endocrine disorders except for diabetes;\n5. use of medications within the last 3 months (i.e., antibiotics or antifungals, corticosteroids, methotrexate, or immunosuppressive cytotoxic agents);\n6. any health conditions deemed to interfere with primary outcomes at the investigator's discretion (e.g., kidney disease, liver disease, cancer, GI surgery, heavy alcohol consumption, etc.);\n7. having a pacemaker or any electrical medical device that prevents the individual from undergoing the bioelectrical impedance analysis bioimmunoassay (BIA) test.\"","24 Years","70 Years",{"count":59,"type":21},156,[24],"The purpose of the study is to ascertain whether traditional kefir not only enhances vascular health but also contributes to improved immune outcomes in both male and female participants at higher risk or living with Type 2 Diabetes (T2D) after 12 weeks of treatment.",[28,63,64],"Diabetes Mellitus, Type 2","Cardiovascular Diseases",[66,67,68,69,70],"Kefir","Systemic inflammation","Vascular markers","Gut microbiota","Fermented Foods","RECRUITING","2026-05-06",{"date":74,"type":41},"2026-05-08",{"date":76,"type":41},"2026-03-24",{"date":78,"type":21},"2027-12",{"name":80,"class":48},"University of Alberta",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":88,"sex":17,"minAge":89,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":93,"conditions":94,"keywords":100,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":49},"100589558","the-effect-of-pectin-supplementation-on-geriatric-with-frailty-a-randomised-placebo-controlled-dietary-intervention-study-100589558","NCT06955975","The Effect of Pectin Supplementation on Geriatric With Frailty: A Randomised Placebo-Controlled Dietary Intervention Study","GEOFF","Inclusion Criteria:\n\n* Participant is willing and able to give informed consent for participation in the study.\n* Participant eligibility includes those aged \\>65 years who have a body mass index (BMI) between 18.5 and 39.9 kg\u002Fm2.\n* Participants who are considered as pre-frail or frail based on FRAIL (Simple Frailty Questionnaire).\n\nExclusion Criteria:\n\n* Have gastrointestinal conditions e.g. malabsorptive conditions such as IBS\u002FIBD, coeliac or functional conditions such as gastroparesis or food intolerances etc.\n* History of major surgery which potentially limit participation or completion of the study.\n* History of gastrointestinal resection surgery, including bariatric surgery.\n* Used of antibiotics, antifungal medications, probiotics or prebiotics 90 days before the start of the study.\n* Are taking the following medications: immunosuppressants, amiodarone and\u002For perhexiline.\n* Are currently following or anticipated to commence a specialised commercially available weight loss diet and\u002For program.\n* History of side effects towards probiotics or prebiotics.\n* History or current psychiatric illness.\n* History or current neurological condition (e.g. epilepsy).\n* Having taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance.",true,"65 Years",{"count":91,"type":21},30,[24],"The study involves the intake of Low-methoxy (LM) pectin (polysaccharides extracted from citrus peels), which are commonly found in the UK diet (not pharmacological agents), to test their effects on systematic inflammation in the body and gut microbiome composition. Study subjects will be healthy elderly with early signs of frailty or pre-frailty from the local population and will be asked to attend the laboratory on 2 occasions; before and after 4-week' supplementing the diet daily with either 10g of pectin with 10g of whey protein and 10g of cocoa powder added as flavour (active arm) or 10g of whey protein with 10g of cocoa powder added as flavour (placebo). Participants will be given the blinded products portioned in individual sachets, with instructions to add the contents of one sachet a day to 150ml of milk and to consume immediately.\n\nAt each study visit (\\~90 minutes), participants will be asked to provide a stool and blood sample, will have blood pressure, heart rate, weight, height, and waist\u002Fhip ratio measured, research team will perform physical functioning test (Time up and go test, 30-second sit to stand test) as well as participants will complete the quality-of-life questionnaire (SF-36), the Depression and Anxiety (HADS) and the Gastrointestinal Symptom Rating Scale (GSRS).",[95,96,97,98,99,28],"Frailty at Older Adults","Pre-Frailty","Frailty","Diet","Dietary Fiber",[101,102,97,96,67,103,104],"Pectin","LM Pectin","Dietary intervention","Gut microbiome","2025-06-17",{"date":107,"type":41},"2025-06-22",{"date":109,"type":41},"2025-02-10",{"date":111,"type":21},"2026-03-31",{"name":113,"class":48},"University of Nottingham",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":88,"sex":17,"minAge":18,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":124,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":49},"100557767","phase-2-pbm-as-strategy-to-cabg-anemic-patients-bypass-graft-cabg-100557767","NCT06542393","PBM as Strategy to CABG Anemic Patients Bypass Graft (CABG)","Patient Blood Manegement (PBM) as Perioperative Strategy to Anemic Patients Who Will be Submitted to Coronary Artery Bypass Graft (CABG).","Inclusion Criteria:\n\n* Eletive surgery;\n* Only CABG as procedure;\n* Off pump CABG candidate.\n\nExclusion Criteria:\n\n* Age \\> 80 years;\n* Chronic dialytic kidney disease;\n* Chronic rheumatologic disease;\n* Men with Hb levels \\> 13 g\u002Fdl and \\\u003C 8g\u002Fdl;\n* Women with Hb levels \\> 12 g\u002Fdl and \\\u003C 8g\u002Fdl;\n* Presence of another heart disease requiring surgical intervention;\n* Presence of hepatic insufficiency;\n* Presence of any implantable electronic cardiac device in any cardiac chambers;\n* Pregnancy;\n* Diagnosis of malignant neoplasia;\n* Thrombophilias;\n* Need for Erythropoietin treatment due to any other disease.\n* Recent ischemic event (\\\u003C 3 months).\n* Ejection fraction \\\u003C30%.","80 Years",{"count":123,"type":21},120,[125],"PHASE2","Anemia poses risks during coronary artery bypass grafting (CABG), increasing complications and mortality rates. Blood transfusions in cardiac surgery have negative outcomes, prompting the use of erythropoietin in Patient Blood Management (PBM) to limit transfusion needs and enhance postoperative recovery. EPO can reduce blood component requirements, adverse events, and inflammation in anemic CABG patients. A study aims to minimize transfusions through a PBM anemia treatment protocol for CABG patients, comparing outcomes in three groups: a Control Group (CG), a Non-PBM Group (NPBMG) treated with blood components, and a PBM Group (GPBM) treated with EPO. Parameters include post-op stay, mortality, cardiovascular events, non-cardiovascular events, ICU time, mechanical ventilation duration, vasoactive drug use, inflammatory responses, and cardiac cell death. Analysis will consider demographic and clinical factors, with expectations that GPBM will yield superior results compared to NPBMG and similar or better outcomes than CG.",[128,129,130,131,132,28,133,134],"Anemia","Coronary Disease","Coronary Artery Disease","Coronary Stenosis","Coronary Occlusion","Bleeding","Epigenetic Disorder","2024-08-04",{"date":137,"type":41},"2024-08-07",{"date":139,"type":41},"2024-06-01",{"date":141,"type":21},"2026-06-01",{"name":143,"class":48},"Federal University of São Paulo"]